All In Biotech

Drug Trial Radar · NCT01459237

Effects of Hormone Stimulation on Brain Scans for Cushing s Disease

Prospective Evaluation of the Effect of Corticotropin-Releasing Hormone Stimulation on 18F-Fludeoxyglucose High-Resolution Positron-Emission Tomography in Cushing's Disease

Last checked: Nov 20, 2026Latest source record: Jun 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Oct 11, 2011

Primary completion

Jan 30, 2018

Study completion Jun 12, 2018

Sponsor

Sponsor type
NIH
First posted
Oct 25, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Single group
Masking
Single (participant)
Primary purpose
Diagnostic
Who can join
All sexes, from 8 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Background: * Cushing s disease can be caused by a tumor of the pituitary gland, a small gland about the size of a pea located at the base of the brain. These tumors produce high levels of hormones, which cause obesity, diabetes, and growth problems. The cure for this type of Cushing s disease is to have surgery that removes the tumor but leaves the pituitary gland alone. Currently, magnetic resonance imaging scans are the best way to find these tumors. However, many of these tumors do not show up on the scan. * Positron emission tomography (PET) scans use radioactive chemicals to light up parts of the body that are more active, such as tumors. Researchers want to try to make the small Cushing s disease tumors more active to help them show up on the scans. A special hormone will be given before the scan to make the tumors more active. Objectives: \- To test the use of hormone stimulation to improve brain scans for Cushing s disease tumors. Eligibility: \- Individuals at least 8 years of age who will be having surgery to remove Cushing s disease tumors. Design: * Participants will be screened with a medical history, physical exam, blood and urine tests, and imaging studies. * They will have three brain scans before surgery. The first scan is a magnetic resonance imaging scan to show a full picture of the brain. The second and third scans are PET scans. * The first PET scan will be given without the special hormone. The second PET scan will be done more than 24 hours but less than 14 days after the first PET scan. The second PET scan will be given with the special hormone. * Participants will have tumor removal surgery through another study protocol.

Conditions

  • Pituitary Neoplasm

Interventions

  • ActhrelDrug

    Ovine Corticorelin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine effect of CRH stimulation on 18F-FDG uptake in high-resolution PET-imaging of ACTH-adenomas in CD.Time frame: Ongoing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institutes of Health Clinical Center, 9000 Rockville Pike

    Bethesda, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.